Clinical trial · Observational
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
NCT03165422CI-TRIAL-00041260completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma in Japan
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adult patients with melanoma
- description
- Adult patients with melanoma at participating centers in Japan
- interventionNames
- Other: Non-Interventional
Primary outcomes (5)
- measure
- Incidence of ipilimumab treatment after nivolumab treatment
- timeFrame
- Approximately 19 months
- measure
- Incidence of nivolumab treatment after ipilimumab treatment
- timeFrame
- Approximately 19 months
- measure
- Duration of nivolumab treatment
- timeFrame
- Approximately 19 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients \> 18 years of age or older * Diagnosis of advanced melanoma (unresectable/metastatic), alive or deceased as of date of data collection * Treated with ipilimumab between 31-Aug-2015 and 31-Mar-2017 before or after nivolumab treatment Exclusion Criteria: * Patients enrolled in any clinical trials at any time * Overlapping use of nivolumab and ipilimumab
References
Publications (0)
Data not yet available
No reference posted for this study.